(Q34561039)

3 August 2017

title

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin (English)

1 reference

3 August 2017

1 reference

Lauri I Kajosaari

1

1 reference

3 August 2017

Jouko Laitila

series ordinal

2

1 reference

3 August 2017

Pertti J Neuvonen

series ordinal

3

1 reference

3 August 2017

Janne T Backman

series ordinal

4

1 reference

3 August 2017

publication date

1 October 2005

1 reference

Basic and Clinical Pharmacology and Toxicology

3 August 2017

published in

1 reference

3 August 2017

volume

97

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

249-256

1 reference

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Human liver microsomal metabolism of paclitaxel and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Rifampin decreases the plasma concentrations and effects of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

The xenobiotic inhibitor profile of cytochrome P4502C8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Examination of 209 drugs for inhibition of cytochrome P450 2C8

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Selective inhibition of human cytochrome P4502C8 by montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO_157.X

10.1111/J.1742-7843.2005.PTO_157.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference